- Home
- FLC vs NERV Comparison
FLC vs NERV Comparison
Compare FLC & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FLC | NERV |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.4M | 166.4M |
| IPO Year | 2003 | 2014 |
Fundamental Metrics
Financial Performance| Metric | FLC | NERV |
|---|---|---|
| Price | $15.67 | $2.53 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.33 |
| AVG Volume (30 Days) | 43.1K | ★ 140.3K |
| Earning Date | 01-01-0001 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,175,600.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.33 | $2.41 |
| 52 Week High | $18.09 | $12.46 |
Technical Indicators
Market Signals| Indicator | FLC | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 44.64 | 22.36 |
| Support Level | $15.33 | N/A |
| Resistance Level | $15.85 | $4.73 |
| Average True Range (ATR) | 0.20 | 0.25 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 76.92 | 2.26 |
Price Performance
Historical ComparisonAbout FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.